December 2, 2021, 11 am – 12 pm PT
Approximately 90% of rheumatoid arthritis patients are prescribed tumor necrosis factor-alpha inhibitor (TNFi) therapies as their first targeted treatment, the world’s most expensive drug class. This is seen through many of these patients will not achieve a clinically meaningful response to these medications; all the while, the patient’s RA is worsening. Come hear how Scipher Medicine, a precision immunology company, is introducing emerging precision diagnostics for immunology. These tests can predict non-response to therapies based on a patient’s individual disease biology addressing one of the biggest challenges in healthcare today.